Viyash Scientific subsidiary partners with Boehringer Ingelheim for pet healthcare

Marquee JV announcedStrategic Transactions View source PDF Explain this filing

VIYASH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.7%Reaction day

₹201.37

prior close

₹204.20

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-2.1%+3.9% vs market

Pharmaceuticals peers, median of 155sector-1.5%+3.3% vs sector

On the reaction day the stock moved 3.9 pts more than Nifty Microcap 250 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.0

15m

+0.2

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.7-2.1+3.9-1.5+3.3

Next day

+1.0-2.0+3.0-2.1+3.1

+1.6-0.0+1.6-1.0+2.6

+0.5-0.4+0.9-1.4+1.9

+1.7+1.4+0.4-1.1+2.8

+1.4+0.1+1.3-1.4+2.8

+7.7+5.2+2.5+1.4+6.3

15d

+4.9+3.7+1.2+0.0+4.9

+8.1+3.5+4.6+0.3+7.8

-10.3-9.4-0.9-9.9-0.4

+5.0+9.0-4.0+2.5+2.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Viyash Scientific's wholly owned subsidiary Alivira Animal Health has signed a partnership with Boehringer Ingelheim India to distribute and promote their companion animal products portfolio across India. Alivira will leverage its extensive sales network to market Boehringer Ingelheim's pet health offerings in urban and rural markets. The deal targets India's growing pet healthcare segment driven by rising pet ownership and preventive care awareness. No financial terms disclosed.

Likely market impact

Strategic entry into India's high-growth pet healthcare segment through a global biopharma partnership, potentially expanding revenue streams.